Alumis Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| ALMS | CRVS | ACRS | AGMB | LYCA | RCUS | |
|---|---|---|---|---|---|---|
| Market cap | 847.80M | 889.16M | 570.34M | 337.35M | 1.51B | 2.43B |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -2.3 | -9.9 | -5.1 | -3.4 | — | -6.2 |
| Price/book | 1.9 | 3.9 | 4.1 | 2.7 | -3.2 | 3.8 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | +38.77% | +35.17% | +62.11% | −53.24% | −3.60% | −1.28% |
| Today | +0.77% | +7.53% | −1.60% | 0.00% | +4.78% | +2.12% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All ALMS news ›Critical Review: Connect Biopharma (NASDAQ:CNTB) & Alumis (NASDAQ:ALMS)
Posted by Michael Walen on Nov 3rd, 2026 Alumis (NASDAQ:ALMS – Get Free Report) and Connect Biopharma (NASDAQ:CNTB – Get Free Report) are both small-cap healthcare companies, but which is the superior stock? We will compare the two…
LINKTOUR Presents the ALUMI Creative Collection at Mondial de l’Auto Paris
Anchored by the philosophy of "Un ALUMI, Trois Arts de Vivre” (One ALUMI, Three Arts of Living), LINKTOUR unveils a creative collection exploring modern urban lifestyles, featuring an exclusive artist collaboration, a Touring-inspired…
Alumis reports sustained scalp and itch improvements with envudeucitinib ahead of filing
South San Francisco-based Alumis Inc. (Nasdaq: ALMS) reported new Phase III data from its ONWARD program showing that envudeucitinib (ESK-001), an investigational oral TYK2 inhibitor, produced durable scalp clearance, itch resolution, and…
Alumis reports 48‑week scalp and itch data from Phase 3 psoriasis program
The continuous-treatment cohort showed symptom gains as Alumis targets a fourth-quarter U.S. drug application. More than 80 per cent of continuously treated patients had clear or almost clear scalps at 48 weeks, as Alumis Inc. NASDAQALMS…
Alumis’ Envudeucitinib Delivers Early and Robust Improvements in Skin Clearance, Quality of Life and Psoriasis Symptoms in Two Phase 3 Trials, Underscoring Its Potential as a Leading Oral Therapy for Plaque Psoriasis
Envudeucitinib also demonstrated improvements in scalp psoriasis, a high-impact, difficult-to-treat area marked by profound effects on quality of life. At Week 24, approximately three out of four envudeucitinib patients1 achieved clear or…
Alumis Announces New Phase 3 Data Demonstrating Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
– Results build on ONWARD3 highest complete skin clearance (54% PASI 100) at Week 48, reinforcing envudeucitinib’s potential to become a leading oral therapy for moderate-to-severe plaque psoriasis – Patients switching from placebo or…
SMM statistics show that this week, the social inventory of cast alumi - Shanghai Metals Market (SMM)
SMM statistics show that this week, the social inventory of cast alumi Shanghai Metals Market Social Inventory of Cast Aluminum Alloy Down by 300 mt, Total Remains Low Post-Holiday Data Source Statement: Except for publicly available…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Themes
Most coverage from
- investors.alumis.com1
- mugglehead.com1
- news.metal.com1
- themarketsdaily.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.